Journal Article

PneuMum: Impact from a randomised controlled trial of maternal 23-valent pneumococcal polysaccharide vaccination on middle ear disease amongst Indigenous infants, Northern Territory, Australia

Binks, Michael J., Morris, Peter S., Nelson, Jane, Andrews, Ross M., Chatfield, Mark D., Balloch, Anne, Tang, Mimi L.K., Moberley, Sarah A., Mulholland, E. Kim, Hare, Kim M., Carapetis, Jonathan R., Wilson, Cate, Leach, Amanda J., Torzillo, Paul, Nelson, Sandra

2015

Overview

•We achieved our intended sample size of 210 participants.•Rates of ear disease (71%) and 23vPPV-type carriage (26%) were lower than expected.•We were unable to show maternal 23vPPV efficacy against infant ear disease or 23vPPV-type carriage.•23vPPV in pregnancy halved infant ear disease concurrent with 23vPPV-type carriage.•23vPPV in pregnancy may complement childhood pneumococcal vaccination programs. We assessed maternal 23-valent pneumococcal polysaccharide (23vPPV) vaccine efficacy (VE) against middle ear disease and pneumococcal carriage amongst Australian Indigenous infants. In an open label, allocation concealed, outcome-assessor blinded, community stratified, randomised controlled trial, healthy pregnant Indigenous women aged 17–39 years in the Northern Territory of Australia received the 23vPPV (1:1:1) at: 30–36 weeks gestation, birth, or were unvaccinated (ClinicalTrials.gov NCT00714064). Co-primary outcomes were the point prevalences of infant middle ear disease and 23vPPV-type carriage at age 7 months. The consent rate was 50% (313/632). Among 227 eligible participants randomised, retention rates were 86% (66/77) controls; 89% (67/75) pregnancy vaccinees; 88% (66/75) birth vaccinees. At infant age 7 months, ear disease prevalence was: 71% (47/66) controls, 63% (42/67) pregnancy vaccinees, 76% (50/66) birth vaccinees; and 23vPPV-type carriage was: 26% (17/66) controls, 18% (12/67) pregnancy vaccinees, 18% (12/66) birth vaccinees. For pregnancy vaccinees, VE was 12% (95% CI −12% to 31%) against infant ear disease and 30% (95% CI −34% to 64%) against 23vPPV-type carriage. In a post-hoc analysis, VE against infant ear disease concurrent with carriage of 23vPPV or related types was 51% (95% CI −2% to 76%). There were no serious adverse effects following receipt of the 23vPPV in pregnancy or at birth. In a high risk population, our study was unable to demonstrate efficacy of 23vPPV in pregnancy against the co-primary outcomes of either all-cause infant ear disease or 23vPPV-type nasopharyngeal carriage at age 7 months. Efficacy against ear disease concurrent with carriage of vaccine-related serotypes (a more specific outcome) suggests 23vPPV in pregnancy may complement childhood pneumococcal vaccination programs.

• Publisher: Elsevier Ltd,Elsevier Limited
• Subject: 23-valent pneumococcal polysaccharide vaccine / Adolescent / Adult / adverse effects / Allergy and Immunology / at-risk population / Australia / Australian Aboriginal and Torres Strait Islander Peoples / Babies / Carrier State - epidemiology / Carrier State - immunology / Carrier State - prevention & control / childhood / disease prevalence / Ear diseases / Female / Humans / Immunity, Maternally-Acquired / Immunization / Indigenous / Infant / Infants / Nasopharynx - microbiology / Northern Territory / Northern Territory - epidemiology / Otitis media / Otitis Media - epidemiology / Otitis Media - immunology / Otitis Media - microbiology / Otitis Media - prevention & control / Pneumococcal Infections - epidemiology / Pneumococcal Infections - prevention & control / Pneumococcal Vaccines - administration & dosage / Pneumococcal Vaccines - immunology / Pneumococcus / Pneumonia / polysaccharides / Pregnancy / Prevalence / randomized clinical trials / serotypes / Streptococcus pneumoniae / Streptococcus pneumoniae - immunology / Streptococcus pneumoniae - isolation & purification / Vaccination / Vaccines / women / Young Adult